Trials / Completed
CompletedNCT00806065
Study of ENMD-2076 in Patients With Multiple Myeloma
A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Safety, tolerability, maximum tolerated dose and clinical benefit of ENMD-2076 administered over a range of doses in patients with relapsed or refractory multiple myeloma.
Detailed description
The study is designed to assess the safety, tolerability, maximum tolerated dose, and clinical benefit of treatment with ENMD-2076 administered orally once daily over a range of doses in patients with relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ENMD-2076 |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2011-11-01
- Completion
- 2012-01-01
- First posted
- 2008-12-10
- Last updated
- 2023-02-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00806065. Inclusion in this directory is not an endorsement.